Idera Pharmaceutical (IDRA) 1.92 $IDRA
Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology
GlobeNewswire - Wed Aug 24, 6:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform.
IDRA: 1.92 (unch)
Idera to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Fri Aug 12, 8:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will provide a corporate overview and participate in a fireside chat discussion at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 12:45 p.m. Eastern Time at the Le Parker Meridien Hotel in New York City.
IDRA: 1.92 (unch)
Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2016.
IDRA: 1.92 (unch)
Idera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3%
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:41AM CDT
Idera Pharmaceuticals, Inc. (IDRA) shares rose over 8% in the last trading session.
IDRA: 1.92 (unch), ANIP: 59.86 (-1.56)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), LGND: 106.19 (-0.85), ACOR: 24.27 (-0.07)
Idera to Present at Two June Investor Healthcare Conferences
GlobeNewswire - Tue Jun 07, 8:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 4:00 p.m. Eastern Time at the Grand Hyatt in New York City.
IDRA: 1.92 (unch)
Idera reports 1Q loss
Automated Insights - Mon May 09, 3:45PM CDT
CAMBRIDGE, Mass. (AP) _ Idera Pharmaceuticals Inc. (IDRA) on Monday reported a loss of $12.8 million in its first quarter.
IDRA: 1.92 (unch)
Idera Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 09, 3:00PM CDT
9 of 10 Waldenstrom's Macroglobulinemia Patients Treated at the Highest Dose have Demonstrated Reductions in IgM or M-Protein Levels in Ongoing Trial
IDRA: 1.92 (unch)
Idera to Release 2016 First Quarter Results on May 9, 2016
GlobeNewswire - Thu May 05, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced that first quarter results for 2016 are expected to be released on Monday, May 9, 2016 after the close of the U.S. Financial Markets.
IDRA: 1.92 (unch)
Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral IMO-2125 and IDO-1 Inhibitor at AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical data demonstrating enhanced systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1). IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera. IDO is one of several immune checkpoints involved in tumor immune escape. IDO-1 inhibitors are currently in clinical development. These data are being presented at the AACR Annual Meeting 2016 in New Orleans, LA.
IDRA: 1.92 (unch)
Idera to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 11, 9:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will present at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York City.
IDRA: 1.92 (unch)
Global Idera Pharmaceuticals, Inc. Market Overview Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:13AM CST
'IDERA PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the IDERA PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
IDRA: 1.92 (unch)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.73 (+0.02), IMMU: 2.74 (+0.06), INCY: 82.02 (+1.21), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), EPZM: 7.16 (-0.15), BIND: 0.78 (-0.09), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), IDRA: 1.92 (unch), CYCC: 5.71 (unch), GILD: 76.89 (-0.53), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), CBMG: 13.94 (-0.55), CELGZ: 1.18 (+0.05)
Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/svzcsv/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Moderate Psoriasis Overview - Therapeutics Development - Pipeline Products for Moderate Psoriasis - Overview - Pipeline Products for Moderate Psoriasis - Comparative Analysis - Moderate Psoriasis - Therapeutics under Development by Companies - Moderate Psoriasis - Therapeutics under Investigation by Universities/Institutes - Moderate Psoriasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Moderate Psoriasis - Products under Development by Companies - Moderate Psoriasis - Products under Investigation by Universities/Institutes - Moderate Psoriasis - Companies Involved in Therapeutics Development - AbGenomics International, Inc. - ADC Therapeutics Sarl - Almirall, S.A. - AstraZeneca Plc - Avexxin AS - Boehringer Ingelheim GmbH - Celgene Corporation - Convoy Therapeutics, Inc. - Crescendo Biologics Limited - Delenex Therapeutics AG - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - GlycoMar Limited - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - OPKO Health, Inc. - Sandoz International GmbH - Soligenix, Inc. - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/svzcsv/moderate
JNJ: 119.32 (+0.24), IDRA: 1.92 (unch), OPK: 9.33 (+0.04), FWP: 19.13 (+0.05), AZN: 33.31 (+0.71), GALT: 1.70 (+0.05), LLY: 76.85 (-0.38), VRX.TO: 37.34 (-0.75), CELGZ: 1.18 (+0.05)
Waldenstrom Macroglobulinemia Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/v6dn7v/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Waldenstrom Macroglobulinemia Overview - Therapeutics Development - Pipeline Products for Waldenstrom Macroglobulinemia - Overview - Pipeline Products for Waldenstrom Macroglobulinemia - Comparative Analysis - Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies - Waldenstrom Macroglobulinemia - Therapeutics under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Waldenstrom Macroglobulinemia - Products under Development by Companies - Waldenstrom Macroglobulinemia - Products under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - BeiGene(Beijing) Co.,Ltd - Calithera Biosciences, Inc. - Celgene Corporation - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - IGF Oncology, LLC. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v6...aldenstrom
INCY: 82.02 (+1.21), IDRA: 1.92 (unch), GILD: 76.89 (-0.53), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05), KPTI: 10.62 (-0.48)
Forget Inovio Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys
Keith Speights, The Motley Fool - Motley Fool - Tue Jan 26, 3:40PM CST
Image Source: Inovio Pharmaceuticals. Sure, the future for the DNA immunotherapies under development by Inovio Pharmaceuticals (NASDAQ: INO) seems very promising. But after a year when Inovio's shares dropped nearly 28%, some investors might be...
INO: 9.08 (-0.06), CARA: 5.32 (-0.06), IDRA: 1.92 (unch), AZN: 33.31 (+0.71)
Why Shares in Idera Pharmaceuticals, Inc. Dropped 10% Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Jan 15, 2:51PM CST
Image source: Idera Pharmaceuticals. W hat: After presenting at the J.P. Morgan healthcare conference on Wednesday and hitting a new 52-week low yesterday, shares in Idera Pharmaceuticals slumped by another 10% earlier today. So what: The...
IDRA: 1.92 (unch)
Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 13, 6:18AM CST
What: Shareholders of Idera Pharmaceuticals , a clinical-stage biopharmaceutical company focused on cancer and other rare diseases, had a rough 2015. The company's shares lost more than 36% of their value in during the year, according to data from...
IDRA: 1.92 (unch), GSK: 44.26 (+1.28)
Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology
GlobeNewswire - Wed Aug 24, 6:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform.
IDRA: 1.92 (unch)
Idera to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Fri Aug 12, 8:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will provide a corporate overview and participate in a fireside chat discussion at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 12:45 p.m. Eastern Time at the Le Parker Meridien Hotel in New York City.
IDRA: 1.92 (unch)
Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2016.
IDRA: 1.92 (unch)
Idera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3%
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:41AM CDT
Idera Pharmaceuticals, Inc. (IDRA) shares rose over 8% in the last trading session.
IDRA: 1.92 (unch), ANIP: 59.86 (-1.56)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), LGND: 106.19 (-0.85), ACOR: 24.27 (-0.07)
Idera to Present at Two June Investor Healthcare Conferences
GlobeNewswire - Tue Jun 07, 8:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 4:00 p.m. Eastern Time at the Grand Hyatt in New York City.
IDRA: 1.92 (unch)
Idera reports 1Q loss
Automated Insights - Mon May 09, 3:45PM CDT
CAMBRIDGE, Mass. (AP) _ Idera Pharmaceuticals Inc. (IDRA) on Monday reported a loss of $12.8 million in its first quarter.
IDRA: 1.92 (unch)
Idera Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 09, 3:00PM CDT
9 of 10 Waldenstrom's Macroglobulinemia Patients Treated at the Highest Dose have Demonstrated Reductions in IgM or M-Protein Levels in Ongoing Trial
IDRA: 1.92 (unch)
Idera to Release 2016 First Quarter Results on May 9, 2016
GlobeNewswire - Thu May 05, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced that first quarter results for 2016 are expected to be released on Monday, May 9, 2016 after the close of the U.S. Financial Markets.
IDRA: 1.92 (unch)
Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral IMO-2125 and IDO-1 Inhibitor at AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical data demonstrating enhanced systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1). IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera. IDO is one of several immune checkpoints involved in tumor immune escape. IDO-1 inhibitors are currently in clinical development. These data are being presented at the AACR Annual Meeting 2016 in New Orleans, LA.
IDRA: 1.92 (unch)
Idera to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 11, 9:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will present at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York City.
IDRA: 1.92 (unch)
Global Idera Pharmaceuticals, Inc. Market Overview Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:13AM CST
'IDERA PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the IDERA PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
IDRA: 1.92 (unch)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.73 (+0.02), IMMU: 2.74 (+0.06), INCY: 82.02 (+1.21), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), EPZM: 7.16 (-0.15), BIND: 0.78 (-0.09), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), IDRA: 1.92 (unch), CYCC: 5.71 (unch), GILD: 76.89 (-0.53), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), CBMG: 13.94 (-0.55), CELGZ: 1.18 (+0.05)
Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/svzcsv/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Moderate Psoriasis Overview - Therapeutics Development - Pipeline Products for Moderate Psoriasis - Overview - Pipeline Products for Moderate Psoriasis - Comparative Analysis - Moderate Psoriasis - Therapeutics under Development by Companies - Moderate Psoriasis - Therapeutics under Investigation by Universities/Institutes - Moderate Psoriasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Moderate Psoriasis - Products under Development by Companies - Moderate Psoriasis - Products under Investigation by Universities/Institutes - Moderate Psoriasis - Companies Involved in Therapeutics Development - AbGenomics International, Inc. - ADC Therapeutics Sarl - Almirall, S.A. - AstraZeneca Plc - Avexxin AS - Boehringer Ingelheim GmbH - Celgene Corporation - Convoy Therapeutics, Inc. - Crescendo Biologics Limited - Delenex Therapeutics AG - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - GlycoMar Limited - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - OPKO Health, Inc. - Sandoz International GmbH - Soligenix, Inc. - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/svzcsv/moderate
JNJ: 119.32 (+0.24), IDRA: 1.92 (unch), OPK: 9.33 (+0.04), FWP: 19.13 (+0.05), AZN: 33.31 (+0.71), GALT: 1.70 (+0.05), LLY: 76.85 (-0.38), VRX.TO: 37.34 (-0.75), CELGZ: 1.18 (+0.05)
Waldenstrom Macroglobulinemia Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/v6dn7v/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Waldenstrom Macroglobulinemia Overview - Therapeutics Development - Pipeline Products for Waldenstrom Macroglobulinemia - Overview - Pipeline Products for Waldenstrom Macroglobulinemia - Comparative Analysis - Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies - Waldenstrom Macroglobulinemia - Therapeutics under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Waldenstrom Macroglobulinemia - Products under Development by Companies - Waldenstrom Macroglobulinemia - Products under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - BeiGene(Beijing) Co.,Ltd - Calithera Biosciences, Inc. - Celgene Corporation - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - IGF Oncology, LLC. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v6...aldenstrom
INCY: 82.02 (+1.21), IDRA: 1.92 (unch), GILD: 76.89 (-0.53), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05), KPTI: 10.62 (-0.48)
Forget Inovio Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys
Keith Speights, The Motley Fool - Motley Fool - Tue Jan 26, 3:40PM CST
Image Source: Inovio Pharmaceuticals. Sure, the future for the DNA immunotherapies under development by Inovio Pharmaceuticals (NASDAQ: INO) seems very promising. But after a year when Inovio's shares dropped nearly 28%, some investors might be...
INO: 9.08 (-0.06), CARA: 5.32 (-0.06), IDRA: 1.92 (unch), AZN: 33.31 (+0.71)
Why Shares in Idera Pharmaceuticals, Inc. Dropped 10% Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Jan 15, 2:51PM CST
Image source: Idera Pharmaceuticals. W hat: After presenting at the J.P. Morgan healthcare conference on Wednesday and hitting a new 52-week low yesterday, shares in Idera Pharmaceuticals slumped by another 10% earlier today. So what: The...
IDRA: 1.92 (unch)
Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 13, 6:18AM CST
What: Shareholders of Idera Pharmaceuticals , a clinical-stage biopharmaceutical company focused on cancer and other rare diseases, had a rough 2015. The company's shares lost more than 36% of their value in during the year, according to data from...
IDRA: 1.92 (unch), GSK: 44.26 (+1.28)
